SW-682 for Solid Tumors
Trial Summary
Will I have to stop taking my current medications?
The trial requires you to stop taking certain medications that affect specific liver enzymes (CYP3A4, CYP1A2, etc.) and other drug transporters at least 14 days before starting the study treatment. It's best to discuss your current medications with the trial team to see if any need to be paused.
What is the purpose of this trial?
This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.
Eligibility Criteria
This trial is for adults with advanced solid tumors that have not improved or worsened after cancer treatments like chemo, immunotherapy, radiation, or targeted therapy. It's also open to those who can't tolerate standard care or have no other options left. Participants must have specific genetic changes in their tumors and be willing to take a new oral medication.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive SW-682 in varying doses to determine the maximum tolerated dose
Dose Expansion
Participants receive SW-682 at the recommended dose for expansion to evaluate efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- SW-682
Find a Clinic Near You
Who Is Running the Clinical Trial?
SpringWorks Therapeutics, Inc.
Lead Sponsor